NCT06144346 Metastases Directed Therapy for Oligometastatic Breast Cancer
| NCT ID | NCT06144346 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Cancer Institute, Egypt |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 150 participants |
| Start Date | 2023-09-20 |
| Primary Completion | 2025-08-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 150 participants in total. It began in 2023-09-20 with a primary completion date of 2025-08-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a phase III randomized study evaluating the benefit from adding metastases directed therapy and locoregional treatment of the primary in breast cancer patients diagnosed with de novo oligometastatic disease patients will be randomized to receive the standard of care (SOC) treatment vs. systemic treatment + Stereotactic Ablative Radiation Therapy. Responders will be randomized to either undergo loco-regional management of the primary tumor or not
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 70 years. * Pathological evidence of breast cancer, any grade, any T stage. * Radiological (at least) evidence of metastatic activity with maximum number of 5 extracranial lesions. * Performance status ≤ 2 * No pre-existing conditions that may prohibit radiotherapy. Exclusion Criteria: •.Pregnant and lactating women. * Prior radiotherapy to affected site(s) in less than a year. * Active Connective tissue diseases (e.g Rheumatoid Arthritis). * Progression to widespread metastatic disease * Cases with brain metastasis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06144346 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 70 Years, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06144346 currently recruiting?
Yes, NCT06144346 is actively recruiting participants. Contact the research team at rimoun.boutrus@nci.cu.edu.eg for enrollment information.
Where is the NCT06144346 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT06144346 clinical trial?
NCT06144346 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 150 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.